AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20737516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (during both phases)
Number of subjects: 39
Study 18717105 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Appraisal techniques
Number of subjects: 0
Study 15679722 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 400 microg nasal spray
Number of subjects: 165
Study 15679722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 15679722 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 100 microg nasal spray
Number of subjects: 165
Study 15679722 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 200 microg nasal spray
Number of subjects: 165
Study 14532926 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC-C (ranitidine bismuth citrate 400 mg plus clarithromycin 500 mg)
Number of subjects: 305
Study 14532926 — intervention group
Group type: COMPARATOR
Intervention: OCA (omeprazole 20 mg, clarithromycin 500 mg and amoxicillin 1000 mg)
Number of subjects: 305
Study 10800385 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum stabilizing system (Vacoped)
Number of subjects: 40
Study 10800385 — intervention group
Group type: COMPARATOR
Intervention: Cast treatment
Number of subjects: 40
Study 8774258 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled respiration at 10 breaths/min while supine
Number of subjects: 21
Study 8774258 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled breathing while standing
Number of subjects: 21
Study 8774258 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled respiration in normal subjects
Number of subjects: 21
Study 8774258 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiration and change in posture
Number of subjects: 21
Study 1419449 — intervention group
Group type: EXPERIMENTAL
Intervention: Open palm technique
Number of subjects: 18
Study 1419449 — intervention group
Group type: COMPARATOR
Intervention: Standard single resuscitator ventilation
Number of subjects: 18
Study 1419449 — intervention group
Group type: COMPARATOR
Intervention: Two-resuscitator ventilation
Number of subjects: 18
Study 1419449 — intervention group
Group type: EXPERIMENTAL
Intervention: Open palm technique (small hands)
Number of subjects: 18
Study 6724467 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline therapy (193.2 mg Theophyllinmonohydrat)
Number of subjects: 10
Study 6724467 — intervention group
Group type: COMPARATOR
Intervention: Systemic application (46.8 mg Aethylendiamin as Euphyllin)
Number of subjects: 10
Study 29172716 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircraft noise exposure (measured in dB(A))
Number of subjects: 1244
Study 29863694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol (200 mg intravenously for 10 days, then 2 tablets 0.125 mg twice a day for 8 weeks)
Number of subjects: 42
Study 29863694 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 42
Study 26018456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IJV cannulation in children
Number of subjects: 37
Study 24969786 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led communication support programme using a Question Prompt List (QPL)
Number of subjects: 0
Study 24969786 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22200763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur (1,000 mg/day for 5 days) + Lentinan (1 mg diluted in 250 ml normal saline)
Number of subjects: 50
Study 22200763 — intervention group
Group type: COMPARATOR
Intervention: Tegafur (1,000 mg/day for 5 days)
Number of subjects: 50
Study 22200763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur + Lentinan
Number of subjects: 50
Study 22200763 — intervention group
Group type: COMPARATOR
Intervention: Tegafur
Number of subjects: 50
Study 20579633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 108
Study 20579633 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 108
Study 18047871 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 12
Study 18047871 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 12
Study 16260972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carbohydrate (CHO) load (20% dextrose solution) during exercise
Number of subjects: 14
Study 16260972 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate (CHO) load (carbohydrate‐rich meal) during exercise
Number of subjects: 14
Study 12113564 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg i.v. droperidol over 5 minutes
Number of subjects: 16
Study 12113564 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline placebo
Number of subjects: 16
Study 10726785 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified gentamicin ointment (1.5%)
Number of subjects: 15
Study 10726785 — intervention group
Group type: COMPARATOR
Intervention: Fortified gentamicin eye drops (1.5%)
Number of subjects: 15
Study 10726785 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ointment and drops
Number of subjects: 15
Study 9195026 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 5% with adrenaline
Number of subjects: 20
Study 9195026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 5% with adrenaline
Number of subjects: 20
Study 1300856 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine (0.5%, 1-1.5 mg kg-1)
Number of subjects: 28
Study 1300856 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (150 micrograms)
Number of subjects: 28
Study 3546148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg b.i.d.
Number of subjects: 45
Study 31362729 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of flipped classroom with problem-based learning (CG)
Number of subjects: 74
Study 31362729 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture‐based classroom (TG)
Number of subjects: 74
Study 30107042 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate (1200 mg elementary calcium/daily)
Number of subjects: 39
Study 30107042 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (1200 mg elementary calcium/daily)
Number of subjects: 39
Study 30107042 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate
Number of subjects: 39
Study 30107042 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 39
Study 27869583 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Age app on a first‐generation iPad
Number of subjects: 17
Study 23225167 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP program (N = 27)
Number of subjects: 52
Study 23225167 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N = 25)
Number of subjects: 52
Study 22465450 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 788
Study 22465450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 788
Study 20032748 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT)
Number of subjects: 151
Study 20032748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast
Number of subjects: 151
Study 20032748 — intervention group
Group type: COMPARATOR
Intervention: Cast and Physiotherapy (PT)
Number of subjects: 151
Study 17493562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch
Number of subjects: 225
Study 17493562 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast
Number of subjects: 225
Study 17493562 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 1 (Breakfast and Lunch)
Number of subjects: 225
Study 17493562 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 2 (Boys and Girls)
Number of subjects: 225
Study 16027399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous epoetin alfa administration
Number of subjects: 64
Study 16027399 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous epoetin alfa administration
Number of subjects: 64
Study 11933904 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM (Type III ZOE cement) mixed at powder:liquid (P:L) ratio of 10g:2g
Number of subjects: 32
Study 11933904 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM (Type III ZOE cement) mixed at powder:liquid (P:L) ratio of 10g:1g
Number of subjects: 32
Study 11933904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no temporary restoration)
Number of subjects: 32
Study 11933904 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly‐carboxylate cement (eugenol‐free) mixed at a P:L ratio of 2.85g:1g
Number of subjects: 32
Study 9880451 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu GM‐CSF (8 microg/kg/d), administered intravenously over 2 hours daily for 7 days and every other day for 21 days
Number of subjects: 264
Study 9880451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 7720346 — intervention group
Group type: EXPERIMENTAL
Intervention: Total enteral nutrition (n = 21)
Number of subjects: 46
Study 7720346 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (n = 25)
Number of subjects: 46
Study 2187723 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha (rIFN-alpha), 10 MU/m2 body surface, intramuscularly, 3 times a week for 3 months
Number of subjects: 24
Study 2187723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 24
Study 2187723 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha (rIFN-alpha)
Number of subjects: 24
Study 31875315 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditions promoting faster performance
Number of subjects: 0
Study 31875315 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditions promoting slower performance
Number of subjects: 0
Study 31407827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hangeshashinto (TJ‐14) 7.5 g/day
Number of subjects: 30
Study 31407827 — intervention group
Group type: COMPARATOR
Intervention: Oral alkalization (sodium bicarbonate 1.8 g/day; ursodeoxycholic acid 300 mg/day)
Number of subjects: 30
Study 29086523 — intervention group
Group type: EXPERIMENTAL
Intervention: Group phone-based weight management intervention
Number of subjects: 142
Study 29086523 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported MVPA
Number of subjects: 142
Study 29086523 — intervention group
Group type: EXPERIMENTAL
Intervention: High loss, low regain group
Number of subjects: 142
Study 29086523 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance phase
Number of subjects: 142
Study 25846144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) for 12 weeks
Number of subjects: 513
Study 25846144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) for 24 weeks
Number of subjects: 513
Study 25846144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) plus ribavirin (RBV) for 12 weeks
Number of subjects: 513
Study 25846144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) plus ribavirin (RBV) for 24 weeks
Number of subjects: 513
Study 25846144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) for 12 weeks without RBV in previously treated patients
Number of subjects: 513
Study 25846144 — intervention group
Group type: COMPARATOR
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) alone
Number of subjects: 513
Study 25846144 — intervention group
Group type: COMPARATOR
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) plus ribavirin (RBV)
Number of subjects: 513
Study 23077973 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime therapy with at least one hypertension medication
Number of subjects: 776
Study 20693243 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol (150 μg once daily)
Number of subjects: 1002
Study 20693243 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 μg twice daily)
Number of subjects: 1002
Study 20693243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study 18825368 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) in patients with vasodilatory shock after cardiac surgery
Number of subjects: 43
Study 18825368 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients undergoing uncomplicated aorto-coronary bypass surgery)
Number of subjects: 43
Study 18825368 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin in patients with vasodilatory shock after cardiac surgery
Number of subjects: 43
Study 18825368 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP response in patients with chronic angiotensin-converting enzyme inhibitor therapy
Number of subjects: 43
Study 17052901 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (7.5mg/h)
Number of subjects: 19
Study 17052901 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (7.5mg/h)
Number of subjects: 19
Study 15288384 — intervention group
Group type: EXPERIMENTAL
Intervention: Trexan and amino-acid therapy
Number of subjects: 1012
Study 15288384 — intervention group
Group type: COMPARATOR
Intervention: Trexan without amino-acid therapy
Number of subjects: 1012
Study 11594942 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants plus zinc (vitamin C 500 mg, vitamin E 400 IU, beta carotene 15 mg, zinc 80 mg)
Number of subjects: 3640
Study 11594942 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc alone (80 mg)
Number of subjects: 3640
Study 11594942 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants alone (vitamin C, E, beta carotene)
Number of subjects: 3640
Study 11594942 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants plus zinc (in higher-risk group)
Number of subjects: 3640
Study 11594942 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (in higher-risk group)
Number of subjects: 3640
Study 11594942 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (in higher-risk group)
Number of subjects: 3640
Study 11594942 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants plus zinc
Number of subjects: 3640
Study 11594942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3640
Study 9756575 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 720
Study 9756575 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch angioplasty closure
Number of subjects: 720
Study 9756575 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation for recurrent stenosis
Number of subjects: 720
Study 7923255 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic stenosis patients
Number of subjects: 27
Study 7923255 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic stenosis patients with changes in collagen architecture
Number of subjects: 27
Study 7923255 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-transplantation donor hearts and normal cardiac function)
Number of subjects: 27
Study 3073804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline (2.5 mg orally three times daily for a week)
Number of subjects: 10
Study 3073804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31315939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic postconditioning plus primary PCI
Number of subjects: 1234
Study 31315939 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (primary PCI)
Number of subjects: 1234
Study 31315939 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI
Number of subjects: 1234
Study 30157911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity (self-report and accelerometry)
Number of subjects: 171
Study 30157911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest levels of lifestyle physical activity
Number of subjects: 171
Study 30157911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity
Number of subjects: 171
Study 27624618 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month strength-based patient navigation interventions with contingency management (PN+CM)
Number of subjects: 0
Study 27624618 — intervention group
Group type: COMPARATOR
Intervention: 6-month strength-based patient navigation interventions without contingency management (PN only)
Number of subjects: 0
Study 27624618 — intervention group
Group type: COMPARATOR
Intervention: Usual care (referral to health care and SUD treatment)
Number of subjects: 0
Study 26656336 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) transfusion in the HAS group
Number of subjects: 47
Study 26656336 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial infusion solutions in the HAS group
Number of subjects: 47
Study 26656336 — intervention group
Group type: COMPARATOR
Intervention: NLAS group (none or low ascites)
Number of subjects: 47
Study 26656336 — intervention group
Group type: COMPARATOR
Intervention: HAS group (high ascites)
Number of subjects: 47
Study 23299383 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily doses of 400 IU of vitamin E and 200 µg of selenium
Number of subjects: 7547
Study 23299383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7547
Study 23299383 — intervention group
Group type: EXPERIMENTAL
Intervention: TICS-M exam
Number of subjects: 7547
Study 21079803 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02(D) vaccine
Number of subjects: 214
Study 21079803 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 214
Study 18042976 — intervention group
Group type: EXPERIMENTAL
Intervention: saline(NEB) + AD
Number of subjects: 20
Study 18042976 — intervention group
Group type: EXPERIMENTAL
Intervention: saline(IPV) + AD
Number of subjects: 20
Study 18042976 — intervention group
Group type: EXPERIMENTAL
Intervention: AD after saline(NEB)
Number of subjects: 20
Study 18042976 — intervention group
Group type: EXPERIMENTAL
Intervention: AD after saline(IPV)
Number of subjects: 20
Study 16582046 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care (IC)
Number of subjects: 1052
Study 16582046 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Specialty Referral (ESR)
Number of subjects: 1052
Study 12919649 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 72
Study 12919649 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 72
Study 10969114 — intervention group
Group type: EXPERIMENTAL
Intervention: Click test for surfactant therapy
Number of subjects: 126
Study 10969114 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical and chest radiograph criteria for surfactant therapy
Number of subjects: 126
Study 10969114 — intervention group
Group type: EXPERIMENTAL
Intervention: Click test and usual criteria
Number of subjects: 126
Study 8993764 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer Factor (TF)
Number of subjects: 20
Study 8993764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1614101 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate 0.1% + diclofenac 0.1% drops
Number of subjects: 40
Study 1614101 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone acetate 0.1% + placebo drops
Number of subjects: 40
Study 6379345 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofensine (2 X 25 mg/day for 30 days)
Number of subjects: 40
Study 6379345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6379345 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofensine
Number of subjects: 40
Study 30300405 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial arch support foot orthoses
Number of subjects: 30
Study 30300405 — intervention group
Group type: COMPARATOR
Intervention: Flat 2‐mm‐thick insoles (sham condition)
Number of subjects: 30
Study 26610637 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser + Ex Regime 2
Number of subjects: 80
Study 26610637 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Ex Regime 1
Number of subjects: 80
Study 26610637 — intervention group
Group type: COMPARATOR
Intervention: Laser + Ex Regime 1
Number of subjects: 80
Study 26610637 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Ex Regime 2
Number of subjects: 80
Study 23775007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 90
Study 23775007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22648842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure
Number of subjects: 45
Study 22648842 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrison
Number of subjects: 45
Study 22648842 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptison
Number of subjects: 45
Study 20174642 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based treatment by Health Extension Workers (HEWs)
Number of subjects: 0
Study 20174642 — intervention group
Group type: COMPARATOR
Intervention: Treatment by general health workers at health facility
Number of subjects: 0
Study 20174642 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based treatment by HEWs
Number of subjects: 0
Study 20174642 — intervention group
Group type: EXPERIMENTAL
Intervention: Involving HEWs in TB treatment
Number of subjects: 0
Study 18662202 — intervention group
Group type: EXPERIMENTAL
Intervention: Napping (self-reported)
Number of subjects: 414
Study 15858317 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐1 (slight facet with wearing of the ink but no indentation on the splint)
Number of subjects: 422
Study 15858317 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐2 (slight indentation on the splint)
Number of subjects: 422
Study 15858317 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐3 (notable indentation on the splint)
Number of subjects: 422
Study 15858317 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations in B‐1, B‐2, B‐3 after 15 years
Number of subjects: 422
Study 15858317 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlay in B‐1, B‐2, B‐3 after 15 years
Number of subjects: 422
Study 15858317 — intervention group
Group type: EXPERIMENTAL
Intervention: Crown in B‐1, B‐2, B‐3 after 15 years
Number of subjects: 422
Study 14563144 — intervention group
Group type: EXPERIMENTAL
Intervention: 700‐cGy external‐beam irradiation to the operative site 24 hours prior to reexploration and decompressive treatment
Number of subjects: 10